Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC grew its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 72.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,836 shares of the company's stock after purchasing an additional 25,505 shares during the quarter. Squarepoint Ops LLC owned approximately 0.13% of Pacira BioSciences worth $1,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in Pacira BioSciences by 16.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock worth $9,462,000 after purchasing an additional 70,307 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares during the last quarter. Empowered Funds LLC lifted its stake in Pacira BioSciences by 5.1% in the fourth quarter. Empowered Funds LLC now owns 229,485 shares of the company's stock worth $4,323,000 after acquiring an additional 11,149 shares during the period. ProShare Advisors LLC grew its position in shares of Pacira BioSciences by 30.2% in the 4th quarter. ProShare Advisors LLC now owns 16,003 shares of the company's stock worth $301,000 after buying an additional 3,710 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Pacira BioSciences by 3.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock worth $491,000 after buying an additional 794 shares during the last quarter. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PCRX shares. HC Wainwright boosted their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. Needham & Company LLC decreased their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Barclays upped their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $26.44.

Pacira BioSciences Trading Up 0.6%

Shares of PCRX stock traded up $0.16 during trading on Tuesday, hitting $26.40. 125,751 shares of the stock traded hands, compared to its average volume of 970,013. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $31.64. The firm's fifty day moving average price is $25.39 and its 200-day moving average price is $23.14. The firm has a market capitalization of $1.22 billion, a P/E ratio of -13.00 and a beta of 0.56. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.